The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines, and significant licence extensions for existing medicines, should be routinely funded by the NHS. The NICE is able to recommend most new medicines for use by the NHS, including as a result of commercial agreements negotiated between NHS England and the company, in line with the commercial framework for new medicines.<\/p>
The NICE develops its guidance in line with its published health technology evaluations manual, which sets out the circumstances in which its Appraisal Committees are able to apply flexibility in the evaluation of specific treatments. The NICE is, for example, able to apply a modifier in the evaluation of medicines for severe diseases that means that its committees are able to recommend medicines at a higher cost-effectiveness threshold than for less severe diseases. The NICE appraises combination therapies using the same methods that it uses for appraising single drug therapies.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-23T16:08:56.173Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Licensing"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what flexibility (a) NICE and (b) NHS England have to approve for use drugs that (i) are used in combination with other drugs, (ii) are used for various (A) conditions and (B) lines of treatment and (iii) provide significant benefits for some but not all patients; and what tools those organisations use to ensure the effectiveness of such appraisals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4370", "label" : {"_value" : "Biography information for Jess Phillips"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Yardley"} , "tablingMemberPrinted" : [{"_value" : "Jess Phillips"} ], "uin" : "27051"} , {"_about" : "http://data.parliament.uk/resources/1719284", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1719284/answer", "answerText" : {"_value" : "
We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10,000 gastro-resistant capsules; Creon 25,000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.<\/p>
Whilst we can\u2019t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-23T15:24:29.583Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pancreatic Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of access to (a) Creon and (b) other drugs that contain pancreatic enzymes for patients after pancreatic surgery.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1493", "label" : {"_value" : "Biography information for Sir Charles Walker"} } , "tablingMemberConstituency" : {"_value" : "Broxbourne"} , "tablingMemberPrinted" : [{"_value" : "Sir Charles Walker"} ], "uin" : "26982"} , {"_about" : "http://data.parliament.uk/resources/1719292", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1719292/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Dissolution.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1719292/answer/previousversion/36822", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} } , "questionFirstAnswered" : [{"_value" : "2024-05-24T14:03:28.23Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prince's Trust: Contracts"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Minister without Portfolio's article of 12 May 2024 in The Sunday Telegraph, when her Department is expected to terminate its contract with the Prince's Trust, order reference C191156; and whether a notice period is required under the provisions of clause 10.2.2 of that contract.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1536", "label" : {"_value" : "Biography information for Emily Thornberry"} } , "tablingMemberConstituency" : {"_value" : "Islington South and Finsbury"} , "tablingMemberPrinted" : [{"_value" : "Emily Thornberry"} ], "uin" : "26990"} , {"_about" : "http://data.parliament.uk/resources/1719342", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1719342/answer", "answerText" : {"_value" : "
The South Asian Biobank, originally funded by the Wellcome Trust, is an international research study designed to prevent the high risk of cardiovascular disease, diabetes, and cancer among South Asian people. The National Institute for Health and Care Research (NIHR) funds research via a range of programmes, with eligibility criteria to support applicants to decide where to apply. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR has provided funding for research projects associated with the South Asian Biobank through open competition, and welcomes any future applications. In addition, the NIHR provides funding to NIHR research infrastructure through open competition. The NIHR Imperial Biomedical Research Centre and the Clinical Research Network have provided support for the South Asian Biobank.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-23", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "27025"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-23T07:42:45.84Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "South Asia Bio Bank: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will have discussions with (a) the National Institute for Health Research and (b) other NHS funding streams on the potential merits of increasing the level of funding made available to the South Asian Biobank to help monitor (i) disease diagnoses and (ii) health outcomes from that project among people from South Asian backgrounds.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4076", "label" : {"_value" : "Biography information for Valerie Vaz"} } , "tablingMemberConstituency" : {"_value" : "Walsall South"} , "tablingMemberPrinted" : [{"_value" : "Valerie Vaz"} ], "uin" : "27023"} , {"_about" : "http://data.parliament.uk/resources/1719343", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1719343/answer", "answerText" : {"_value" : "
The scientific and ethical impacts of cohort diversity on the generalisability of research findings is part of ongoing conversations on health data, including with UK Biobank. As a funder, the Government routinely engages in discussions about diversity with UK Biobank through the Medical Research Council and National Institute for Health and Care Research. The Department is committed to increasing participation of ethnic minority groups in health and social care research, and is working in partnership with diverse communities to ensure they have a stronger voice in shaping priorities for research, the design and delivery of research, inclusive recruitment into studies, and the mobilisation of evidence into practice.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1719343/answer/previousversion/36821", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} } , "questionFirstAnswered" : [{"_value" : "2024-05-24T13:29:24.8Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "UK Biobank: Ethnic Groups"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) UK Biobank and (b) UK Biobank funders on the adequacy of the proportion of UK Biobank participants from BAME backgrounds.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4076", "label" : {"_value" : "Biography information for Valerie Vaz"} } , "tablingMemberConstituency" : {"_value" : "Walsall South"} , "tablingMemberPrinted" : [{"_value" : "Valerie Vaz"} ], "uin" : "27024"} , {"_about" : "http://data.parliament.uk/resources/1719345", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1719345/answer", "answerText" : {"_value" : "
The South Asian Biobank, originally funded by the Wellcome Trust, is an international research study designed to prevent the high risk of cardiovascular disease, diabetes, and cancer among South Asian people. The National Institute for Health and Care Research (NIHR) funds research via a range of programmes, with eligibility criteria to support applicants to decide where to apply. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR has provided funding for research projects associated with the South Asian Biobank through open competition, and welcomes any future applications. In addition, the NIHR provides funding to NIHR research infrastructure through open competition. The NIHR Imperial Biomedical Research Centre and the Clinical Research Network have provided support for the South Asian Biobank.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-23", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "27023"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-23T07:42:45.887Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "South Asia Bio Bank: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of increasing the level of funding allocated to the South Asian Biobank.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4076", "label" : {"_value" : "Biography information for Valerie Vaz"} } , "tablingMemberConstituency" : {"_value" : "Walsall South"} , "tablingMemberPrinted" : [{"_value" : "Valerie Vaz"} ], "uin" : "27025"} , {"_about" : "http://data.parliament.uk/resources/1719358", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1719358/answer", "answerText" : {"_value" : "
While this information is not held in the requested format, the following table shows the laboratory reported figures for cryptosporidiosis, and the reports of cryptosporidiosis per 100,000 people, in England and Wales, each year from 2008 to 2017:<\/p>
Year<\/p><\/td> | Number of laboratory reports<\/p><\/td> | per 100,000 population<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2008<\/p><\/td> | 4,162<\/p><\/td> | 7.6<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2009<\/p><\/td> | 4,831<\/p><\/td> | 8.7<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2010<\/p><\/td> | 3,901<\/p><\/td> | 7.0<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2011<\/p><\/td> | 2,990<\/p><\/td> | 5.3<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2012<\/p><\/td> | 5,765<\/p><\/td> | 10.2<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2013<\/p><\/td> | 3,520<\/p><\/td> | 6.2<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2014<\/p><\/td> | 4,023<\/p><\/td> | 7.0<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2015<\/p><\/td> | 5,222<\/p><\/td> | 9.0<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2016<\/p><\/td> | 5,925<\/p><\/td> | 10.1<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||
2017<\/p><\/td> | 4,292<\/p><\/td> | 7.3<\/p><\/td><\/tr><\/tbody><\/table> In addition, the following table shows the regional distribution of the laboratory reports of cryptosporidium in England and Wales, in 2017:<\/p>
|